Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

American Heart Journal

Volumn 170, Issue 6, 2015, Pages 1151-1160

  Aulin, Julia ^a   Siegbahn, Agneta ^a   Hijazi, Ziad ^a   Ezekowitz, Michael D ^b   Andersson, Ulrika ^a   Connolly, Stuart J ^c   Huber, Kurt ^d   Reilly, Paul A ^e   Wallentin, Lars ^a   Oldgren, Jonas ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d Wilhelminenhospital   (Austria)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; DABIGATRAN; IL6 PROTEIN, HUMAN; WARFARIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DISEASE MARKER; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; MYOCARDIAL INFARCTION; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOMARKERS; C-REACTIVE PROTEIN; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; INTERLEUKIN-6; MALE; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 84949503254     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.09.018     Document Type: Article

References (29)

1. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, and et al. Impact of atrial fibrillation on the risk of death: The Framingham heart study Circulation 98 1998 946 952
2. W.B. Kannel, P.A. Wolf, E.J. Benjamin, and et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates Am J Cardiol 82 1998 2N 9N
3. G.Y. Lip, R. Nieuwlaat, R. Pisters, and et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach Chest 137 2010 263 272
4. Z. Hijazi, J. Oldgren, U. Andersson, and et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy Circulation 125 2012 1605 1616
5. Z. Hijazi, S.H. Hohnloser, J. Oldgren, and et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY trial analysis Circulation 129 2014 961 970
6. W.H. Yin, J.W. Chen, H.L. Jen, and et al. Independent prognostic value of elevated high-sensitivity c-reactive protein in chronic heart failure Am Heart J 147 2004 931 938
7. B. Lindahl, H. Toss, A. Siegbahn, and et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease N Engl J Med 343 2000 1139 1147
8. P.M. Ridker, C.P. Cannon, D. Morrow, and et al. C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
9. P.M. Ridker, M. Cushman, M.J. Stampfer, and et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
10. E. Lindmark, E. Diderholm, L. Wallentin, and et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease JAMA 286 2001 2107 2113
11. J. Danesh, S. Lewington, S.G. Thompson, and et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis JAMA 294 2005 1799 1809
12. J.M. Sinning, C. Bickel, C.M. Messow, and et al. Impact of c-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: The atherogene study Eur Heart J 27 2006 2962 2968
13. T.T. Issac, H. Dokainish, and N.M. Lakkis Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data J Am Coll Cardiol 50 2007 2021 2028
14. D.S. Conway, P. Buggins, E. Hughes, and et al. Prognostic significance of raised plasma levels of interleukin-6 and c-reactive protein in atrial fibrillation Am Heart J 148 2004 462 466
15. A. Pinto, A. Tuttolomondo, A. Casuccio, and et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation Clin Sci (Lond) 116 2009 781 789
16. V. Roldan, F. Marin, J. Diaz, and et al. High sensitivity cardiac troponin t and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation J Thromb Haemost 10 2012 1500 1507
17. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
18. M.D. Ezekowitz, S. Connolly, A. Parekh, and et al. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran Am Heart J 157 2009 805 810
19. S.H. Hohnloser, J. Oldgren, S. Yang, and et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial Circulation 125 2012 669 676
20. F.E. Harrell, K.L. Lee, and D.B. Mark Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
21. M.J. Pencina, R.B. D'Agostino, and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
22. G.Y. Lip, J.V. Patel, E. Hughes, and et al. High-sensitivity c-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors, stroke risk stratification schema, and prognosis Stroke 38 2007 1229 1237
23. P. Patel, H. Dokainish, P. Tsai, and et al. Update on the association of inflammation and atrial fibrillation J Cardiovasc Electrophysiol 21 2010 1064 1070
24. J. Sundelof, L. Kilander, J. Helmersson, and et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: A prospective population-based study J Alzheimers Dis 18 2009 79 87
25. G.M. Marcus, M.A. Whooley, D.V. Glidden, and et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul study Am Heart J 155 2008 303 309
26. V. Roldan, F. Marin, A.D. Blann, and et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation Eur Heart J 24 2003 1373 1380
27. T.E. Strandberg, H. Vanhanen, and M.J. Tikkanen Effect of statins on C-reactive protein in patients with coronary artery disease Lancet 353 1999 118 119
28. D.S. Conway, P. Buggins, E. Hughes, and et al. Relationship of interleukin-6 and c-reactive protein to the prothrombotic state in chronic atrial fibrillation J Am Coll Cardiol 43 2004 2075 2082
29. Y. Guo, G.Y. Lip, and S. Apostolakis Inflammation in atrial fibrillation J Am Coll Cardiol 60 2012 2263 2270